Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denikitug in advanced solid tumors
NCT05007782Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2021
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of denikitug in solid tumor (advanced stage) (6 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Dose Limiting Toxicities, Percentage of Participants Experiencing Adverse Events and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
denikitug
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05007782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007782.